Connection

JOHN KIRKWOOD to HLA-DR Antigens

This is a "connection" page, showing publications JOHN KIRKWOOD has written about HLA-DR Antigens.
Connection Strength

0.669
  1. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res. 2002 Jan 01; 62(1):213-8.
    View in: PubMed
    Score: 0.195
  2. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res. 2000 Sep 01; 60(17):4946-52.
    View in: PubMed
    Score: 0.178
  3. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J Immunol. 2005 Feb 01; 174(3):1751-9.
    View in: PubMed
    Score: 0.060
  4. The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells. Cancer Res. 2003 Oct 01; 63(19):6506-15.
    View in: PubMed
    Score: 0.055
  5. MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. Clin Cancer Res. 2003 Mar; 9(3):947-54.
    View in: PubMed
    Score: 0.053
  6. Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma. Cancer. 2000 Jun 15; 88(12):2693-702.
    View in: PubMed
    Score: 0.044
  7. In vivo biological response to recombinant interferon-gamma during a phase I dose-response trial in patients with metastatic melanoma. J Clin Oncol. 1990 Jun; 8(6):1070-82.
    View in: PubMed
    Score: 0.022
  8. Cross-reactive CD4+ T cells against one immunodominant tumor-derived epitope in melanoma patients. J Immunol. 2007 Dec 01; 179(11):7932-40.
    View in: PubMed
    Score: 0.018
  9. Antigenic phenotype of pigment cell lesions: a study of melanoma, its precursor lesions and heterogeneity in metastatic melanoma. J Invest Dermatol. 1985 May; 84(5):430-2.
    View in: PubMed
    Score: 0.015
  10. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med. 2002 Sep 02; 196(5):619-28.
    View in: PubMed
    Score: 0.013
  11. Automatic multiparameter fluorescence imaging for determining lymphocyte phenotype and activation status in melanoma tissue sections. Cytometry. 1996 Sep 01; 25(1):71-81.
    View in: PubMed
    Score: 0.008
  12. Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design. Clin Cancer Res. 1996 Jan; 2(1):29-36.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.